Research on Alzheimer's disease, from early signs to new therapies. Covers screening tools, brain damage mechanisms, risk factors, sleep, and drug targets.
A study published in Nature Communications sheds light on the critical role of P4-ATPases, particularly ATP8B1-CDC50A, in maintaining lipid asymmetry in cell membranes. The research team used cryo-electron microscopy to determine the structure and function of the human flippase complex, revealing its regulation by phosphoinositides.
Researchers identified cell-type-specific genetic risk scores associated with distinct stages of Alzheimer's disease progression, including amyloid-β accumulation and tau tangle formation. Astrocyte-specific risk contributed to earlier stages, while microglia-specific risk played a role in later phases.
Researchers found 48% of Ojibwe tribal elders reported frequent visions of benevolent spiritual beings and/or ancestors. The study emphasizes the importance of cultural context in diagnosis to avoid misdiagnosis of neuropsychiatric disease.
Researchers have developed new tools to assess disease progression of Alzheimer's disease in animal models, providing a translational approach for studying the disease. The tools use neuroimaging and network modeling techniques to analyze metabolic changes in the brain, confirming previous clinical findings.
Research reveals that people with high conscientiousness and extraversion traits are less likely to receive a dementia diagnosis, unlike those with neuroticism and negative affect. The study analyzed data from over 44,000 individuals and found no link between personality traits and actual brain pathology.
Research found a significant linear relationship between age of coronary heart disease onset and dementia, highlighting the detrimental influence of premature cardiovascular events on brain health. Adults diagnosed with coronary heart disease at a young age may be at increased risk of developing dementia, Alzheimer's disease, and vascu...
A study will examine the cognitive function of older adults who were exposed to measles during childhood, shedding light on potential long-term benefits of routine childhood vaccinations. The research aims to better understand how childhood experiences shape health and well-being across the life course.
A new study from the University of Eastern Finland found that individuals with higher wealth levels had greater hospital care and medication costs before diagnosis. However, after diagnosis, wealth was associated with lower healthcare costs due to differences in comorbidities among different wealth groups.
A two-year study found that participants who received personalized coaching experienced a modest boost in cognitive testing, measuring a 74% improvement over the non-intervention group. Additionally, improvements were noted between the two groups in measurements of risk factors and quality of life.
Researchers have discovered a bidirectional interaction between amyloid-beta protein and sulfatides that may play a key role in the development of Alzheimer
A study by Brigham investigators found that genetic changes in microglia contribute to neuroinflammation, a key factor in Alzheimer's disease progression. Lower levels of INPP5D gene led to increased inflammation and risk for AD.
A research team at HKUST has identified VCAM1, a cell surface protein on immune cells of the brain, as a therapeutic target for Alzheimer's disease. They found that stimulating the VCAM1-APOE pathway reduces AD pathology in a mouse model.
A study found that Black patients undergo medical imaging for cognitive impairment years later than white and Hispanic patients, with significantly lower rates of MRI testing. This delay can lead to earlier stages of disease diagnosis and reduced treatment options.
Research reveals that brain inflammation is the primary cause of neuropsychiatric symptoms in Alzheimer's disease, including irritability, agitation, and anxiety. The study found a strong association between microglial activation and neuropsychiatric symptom severity, suggesting new pathways for therapy development.
Researchers at UCSF and Kaiser Permanente Washington found that participants who received personalized coaching experienced a 74% improvement in cognitive testing compared to non-intervention participants. The study also showed improvements in risk factors and quality of life, with modest but significant increases in cognitive function.
A team of researchers at Massachusetts General Hospital has identified a new small molecule inhibitor, PB118, that significantly reduces Alzheimer's disease neuropathology. The inhibitor targets histone deacetylase 6 (HDAC6), which is overexpressed in the brain of AD patients.
Researchers investigate whether Tau proteins play a previously unsuspected role in energy management of neurons, potentially leading to new treatment options. The study aims to clarify the role of Tau in energy management and explore novel approaches to develop it into a target for therapies.
Researchers have found that lowering a form of brain cholesterol known as cholesteryl esters helps prevent brain damage and behavioral changes in mice with Alzheimer's-like tau deposits. The study suggests that reducing cholesteryl ester levels could be a promising candidate to test in neurodegenerative diseases.
UTEP researchers develop a therapy based on caffeic-acid derived from spent coffee grounds to protect brain cells from damage. The treatment has potential to prevent neurodegenerative disorders such as Alzheimer's and Parkinson's by removing free radicals and inhibiting amyloid protein aggregation.
Researchers analyzed genes and brain tissue of patients with Alzheimer's disease to find sex-specific differences in immune function, cellular metabolism, and communication between brain cells. The study suggests that these differences contribute to women's increased risk for the disease and its severity.
Researchers at Chalmers University of Technology have discovered a new method for capturing proteins in nano-sized traps to study difficult-to-treat diseases. The technique allows for the trapping of hundreds of proteins in a small volume, enabling the study of early development and potential drug countermeasures.
A study published at the Radiological Society of North America annual meeting found that higher amounts of visceral abdominal fat in midlife are associated with increased risk of Alzheimer's disease. The research also showed that this type of fat is linked to brain inflammation, which may contribute to the development of the disease.
Researchers at the University of Wisconsin-Madison have successfully generated human norepinephrine neurons from stem cells using a key protein called ACTIVIN-A. These LC-NE neurons may serve as models for disease in humans, enabling scientists to screen drugs and answer questions about neurodegeneration.
Researchers at The University of Texas at Dallas discovered distinct changes in brain network patterns associated with early-stage Alzheimer’s disease, affecting sensory and motor processing. These findings offer new insights into the broader impact of Alzheimer’s on brain function and potential targets for treatment.
A new study reveals that a genetic mutation in microglia can elevate Alzheimer's risk by reducing brain circuit connections, promoting inflammation, and impairing debris clearance. The mutation affects the TREM2 protein, leading to increased expression of inflammatory genes and impaired response to neuron injury.
A new study published in Neurology finds that shrinkage in the hippocampus area of the brain is associated with cognitive decline, regardless of amyloid plaques. The study involved 128 participants and found that faster hippocampus atrophy was linked to faster cognitive decline.
Researchers at UMass Lowell found that anti-inflammatory bacteria were less abundant in people with Parkinson's disease, suggesting a potential biomarker for early diagnosis. A new study on Latinos may also uncover novel biomarkers for Alzheimer's disease.
Researchers characterized changes in cognitive behaviors, neuronal morphology and gene expression in a tauopathy mouse model. The study found significant decreases in dendritic arborization and synaptic gene upregulation over time.
Researchers discovered that the Christchurch mutation blocks the detrimental effects of apolipoprotein E4 on Alzheimer's disease by reducing tau protein accumulation and neuroinflammation. This genetic variant may offer novel therapeutic interventions to mimic its protective effects.
Researchers developed a handheld, wireless biosensor to detect Alzheimer's and Parkinson's biomarkers from saliva and urine samples. The device has shown high accuracy comparable to existing state-of-the-art methods.
Researchers have discovered the temporal structure of hippocampal ripples, a type of brain wave associated with memory consolidation. The study uses topological data analysis to classify these ripples and predict their generation by different regions of the hippocampus, offering new insights into episodic memory formation.
Earlier onset of atrial fibrillation is associated with an elevated risk of subsequent all-cause dementia, Alzheimer's disease, and vascular dementia. Monitoring cognitive function among patients with atrial fibrillation, especially those younger than 65 years at diagnosis, is crucial.
Researchers at Texas A&M University have found a correlation between flavonoid compounds and reduced endometriosis symptoms. Flavonoids like Quercetin and Kaempferol show promise in easing inflammation, with studies suggesting they may help suppress the symptoms of inflammatory diseases like endometriosis.
Researchers at Karolinska Institutet have discovered that a metabolic increase in the hippocampus is an early indicator of Alzheimer's disease. The study found that changes in mitochondrial metabolism precede synaptic disorganization and impaired autophagy, highlighting potential new methods for early intervention.
A research team has developed a new method for mapping brain activity to understand behavior changes in patients with neurological disease. The technique uses CaMPARI images to track brain activity and can be used to study the effects of Alzheimer's disease on brain function.
Two new studies suggest that of the 8 million Americans who have MCI, more than 90% don’t know it. Early diagnosis is key to delaying onset of dementia and Alzheimer’s disease. Researchers found that detection of MCI was poorer in those with cardiovascular disease, diabetes, hypertension, and other health issues.
A Cornell University-led study has separated the role of the hippocampus in two functions of memory, which are crucial for associating time, place, and past experiences with future actions. The breakthrough has significant implications for treating memory and learning issues found in Alzheimer's disease and dementia.
Researchers at Gladstone Institutes found that ApoE4-producing neurons release HMGB1, triggering microglial activation and neurodegeneration. Blocking HMGB1 with experimental drugs offers strong protection against APOE4-driven neurodegeneration.
A review in the Journal of Neurochemistry suggests a link between COVID-19 and Alzheimer's disease, with age being the largest contributing factor. Emerging evidence may further support this association, with research assessing influences on AD neuropathology.
A new study validates an MRI biomarker for early onset Alzheimer's disease, identifying a signature pattern of cortical atrophy that replicates across independent samples. The EOAD signature demonstrates clinical validity and accurately differentiates patients with EOAD from healthy controls and those with other cognitive impairments.
Researchers have developed a new model that replicates key facets of Alzheimer's disease progression in the brain, enabling better understanding of how the disease develops and affects the brain. The model uses induced pluripotent stem cells to study human brain cells with the same genetic background as patients, revealing critical cha...
A new study reveals female sex hormones play a crucial role in how Alzheimer's manifests in the brain, with estradiol contributing to variation in beta-amyloid protein regulation. This understanding is necessary for developing targeted therapies.
Researchers have found that Alzheimer's symptoms can be transferred to healthy young organisms via the gut microbiota, confirming its role in the disease. The study supports the emergence of the gut microbiome as a key target for investigation in Alzheimer's disease.
Researchers discovered how the fungus Candida albicans enters the brain, activates mechanisms to clear itself, and generates amyloid beta-like peptides, contributing to Alzheimer's disease development. The study highlights the importance of understanding fungal involvement in neurodegenerative conditions.
A new study by Boston University School of Public Health finds that adults with Down syndrome are more consistently enrolled in Medicaid and utilize more healthcare services than people without developmental disabilities. However, racial disparities exist, with White individuals having greater access to care.
A recent study published in Nature Medicine suggests that complement proteins and microglia can be activated early in the development of Huntington's Disease, leading to synapse loss and cognitive decline. By blocking these proteins, researchers were able to prevent or slow cognitive defects and motor symptoms in animal models.
A new trial combining an Alzheimer's medication with two other drugs may amplify its effects and arrest disease progression. The trial, funded by a $150M grant, will recruit 900 participants with early-onset Alzheimer's.
The UK Biobank study found that racial minority status increased dementia risk by 24%, with socio-economic status attenuating this effect. Lifestyle factors such as diet, smoking, physical activity, and sleep were identified as crucial in reducing racial and socio-economic disparities in dementia.
Researchers have developed a new microscopy technique using STED technology to visualize individual fibers in amyloid plaques, providing higher resolution than conventional light microscopy. This breakthrough allows for better understanding of the structure and morphology of Aβ aggregates and their role in Alzheimer's disease progression.
A clinical trial led by Western Sydney University's NICM Health Research Institute has revealed that Sailuotong, a novel herbal extract, shows promise as a potential treatment for mild cognitive impairment. The study found improvements in memory and executive function in participants taking SLT compared to those on a placebo.
A new study analyzing English primary care records found that hypertension, obesity, diabetes, and low HDL cholesterol confer a higher risk of dementia in South Asian and Black people compared to White individuals. The results suggest tailored dementia prevention efforts should be targeted towards minority ethnic groups.
Researchers at the University of Arizona Health Sciences will train the next generation of translational scientists in Alzheimer's disease research through a $1.4 million grant. The program aims to develop highly trained, cross-disciplinary researchers to address the complex challenges of this devastating neurodegenerative disorder.
A study using virtual reality led by UCL researchers found people with early Alzheimer's consistently overestimated turns and showed increased variability in sense of direction. These specific impairments were not observed in healthy older participants or those with mild cognitive impairment.
Researchers at Mount Sinai Hospital developed an algorithm called HistoAge that predicts age at death based on human brain tissue specimens using artificial intelligence, revealing insights into aging mechanisms and neurodegenerative diseases like Alzheimer's disease.
A new study has identified two main pathways involved in Alzheimer's disease, with one acting through amyloid and tau proteins and the other based on immune system reactions. The research also found that certain genes have opposite effects in men and women, suggesting a need for further investigation.
Scientists at Temple University's Alzheimer's Center have identified a promising new therapeutic target for Alzheimer's disease: the protein ABCA7. The study found that cholesterol depletion and inflammation suppress ABCA7 levels in human brain cells, potentially contributing to disease onset.
A new study aims to identify environmental and social factors contributing to Alzheimer's disease in older Black adults, who are up to two times more likely to develop the condition. Using remote cognitive assessments and biomarkers, researchers hope to gain a better understanding of the biopsychosocial factors behind this disparity.
Researchers at Chalmers University of Technology have shown that graphene oxide nanoflakes can reduce the accumulation of misfolded amyloid peptides in yeast cells, which are similar to human neurons affected by Alzheimer's disease. This suggests that graphene oxide may hold great potential for treating neurodegenerative diseases.
New research from Cold Spring Harbor Laboratory explores how adult brains adapt through critical periods of learning, such as caring for young. MECP2 dysfunction causes neurodevelopmental disorder Rett syndrome, but the study finds that brain circuits can be rapidly rewired in adults.
A team of researchers from Mass General Brigham has developed a monoclonal antibody that reduces abnormal tau proteins associated with Alzheimer's disease in a preclinical model. The therapy, inspired by a genetic variant that provides resistance against the disease, offers an alternative approach to existing treatments.